公司报告本季度总产品销售额略有下降,为2870万美元,低于上一季度的3070万美元,主要是由于INDOCIN销售额下降。尽管整体销售有所下滑,但Assertio的旗舰产品ROLVEDON仍保持了1500万美元的稳定销售。公司正专注于增长机会,特别是通过扩大ROLVEDON的市场存在和利用尚未 ...

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time, I would like to welcome everyone to ...

Thank you for standing by. My name is John, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings third-quarter results conference call.

Third Quarter Total Net Product Sales of $28.7 MillionRolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 ...

The company achieved an adjusted EBITDA of $5.3 million, primarily driven by reduced selling, general, and administrative expenses. Sales of Rolvedon remained stable, while Indocin sales faced ...

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) ...

You may be keeping tabs on your salt intake and clocking your steps, but did you know that certain everyday medications could be sneaking up on your blood %% ...

In the U.S., six non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used to manage pain and inflammation. While this drug class is widely relied upon, it is also associated with ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

We believe the timeline for the Spectrum acquisition was rushed because Assertio’s leadership was aware that its own flagship product, Indocin, was at imminent risk of losing exclusivity and facing ...